Use of TNFα inhibitor for treatment of psoriasis

  • US 8,986,693 B1
  • Filed: 10/09/2014
  • Issued: 03/24/2015
  • Est. Priority Date: 04/09/2004
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis a first dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said first dosing, wherein the patient achieves at least Psoriasis Area and Severity Index (PASI) 90 response at week 12 of the treatment.

View all claims

    Thank you for your feedback